This study combined data from multiple sources to look at how the brain uses glucose in late-onset neurodegenerative diseases. It included 5,412 individuals with conditions like Alzheimer's, Parkinson's, ALS, and Multiple Sclerosis, along with 3,549 healthy controls. Scientists used FDG-PET scans to measure brain glucose uptake and compared these findings using advanced statistical methods.
The main finding was that dysregulated glucose metabolism appears to be a unifying feature across all the studied diseases. While the overall pattern of metabolic change is common, the specific locations and types of changes—whether too little or too much glucose use—are unique to each disease. These metabolic shifts are also linked to complex neurological functional profiles.
Researchers noted that areas showing high glucose activity, or hypermetabolism, might not always mean the disease is worsening. Instead, this increased activity could represent a compensatory response, a maladaptive process, or a sign of neuroinflammation. Because of this uncertainty, the study suggests that preventing or treating these diseases may require addressing these metabolic issues alongside traditional disease-specific drivers.
Readers should understand that this is a meta-analysis of existing scan data, not a new clinical trial. The results highlight a shared biological mechanism but do not yet offer a new treatment. More focused investigation is needed to fully understand what hypermetabolism means in the context of these progressive conditions.
